PMCB PHARMACYTE BIOTECH INC revenue, earnings and financials
For the quarter ended July 31, 2026, PHARMACYTE BIOTECH INC reported revenue of $0, net income of −$5.08M and diluted EPS of −$0.54; over the last four quarters revenue was $0 and net income −$16.1M; for the fiscal year ended April 2026 revenue was $0.
PMCB annual revenue and earnings
- Fiscal year ended Apr 2026: revenue $0, gross profit n/a, operating income −$6.85M, net income −$19.4M (margin n/a), EPS −$2.77
- Fiscal year ended Apr 2025: revenue $0, gross profit n/a, operating income −$4.38M, net income $30.7M (margin n/a), EPS $3.19
- Fiscal year ended Apr 2024: revenue $0, gross profit n/a, operating income −$8.52M, net income $334K (margin n/a), EPS −$1.80
- Fiscal year ended Apr 2023: revenue $0, gross profit n/a, operating income −$6.46M, net income −$4.32M (margin n/a), EPS −$0.22
- Fiscal year ended Apr 2022: revenue $0, gross profit n/a, operating income −$4.39M, net income −$4.24M (margin n/a), EPS −$0.27
PMCB quarterly revenue and earnings
- Quarter ended Jul 31, 2026: revenue $0, net income −$5.08M, EPS −$0.54
- Quarter ended Apr 30, 2026 (from the annual report): revenue $0, net income −$4.39M, EPS −$0.13
- Quarter ended Jan 31, 2026: revenue $0, net income $747K, EPS −$0.17
- Quarter ended Oct 31, 2025: revenue $0, net income −$7.42M, EPS −$1.24
- Quarter ended Jul 31, 2025: revenue $0, net income −$8.36M, EPS −$1.23
- Quarter ended Apr 30, 2025 (from the annual report): revenue $0, net income $11.7M, EPS $2.12
- Quarter ended Jan 31, 2025: revenue $0, net income −$3.05M, EPS −$0.44
- Quarter ended Oct 31, 2024: revenue $0, net income −$1.47M, EPS −$0.39
- Quarter ended Jul 31, 2024: revenue $0, net income $23.4M, EPS $1.90
- Quarter ended Apr 30, 2024 (from the annual report): revenue $0, net income $1.35M, EPS −$0.35
- Quarter ended Jan 31, 2024: revenue $0, net income −$620K, EPS −$0.65
- Quarter ended Oct 31, 2023: revenue $0, net income $2.79M, EPS −$0.26
- Quarter ended Jul 31, 2023: revenue $0, net income −$3.18M, EPS −$0.54
- Quarter ended Apr 30, 2023 (from the annual report): revenue $0, net income −$126K, EPS −$0.02
- Quarter ended Jan 31, 2023: revenue $0, net income −$764K, EPS −$0.04
- Quarter ended Oct 31, 2022: revenue $0, net income −$1.88M, EPS −$0.09
- Quarter ended Jul 31, 2022: revenue $0, net income −$1.55M, EPS −$0.07
- Quarter ended Apr 30, 2022 (from the annual report): revenue $0, net income −$1.42M, EPS $0.47
- Quarter ended Jan 31, 2022: revenue $0, net income −$811K, EPS −$0.04
- Quarter ended Oct 31, 2021: revenue $0, net income −$980K, EPS −$0.06
PMCB cash flow, buybacks and dividends
- Fiscal year ended Apr 2026: operating cash flow −$5.15M, share buybacks $402K
- Fiscal year ended Apr 2025: operating cash flow −$2.98M, share buybacks $2.54M
- Fiscal year ended Apr 2024: operating cash flow −$2.15M, share buybacks $28.2M
- Fiscal year ended Apr 2023: operating cash flow −$3.79M, share buybacks $13.6M
- Fiscal year ended Apr 2022: operating cash flow −$4.12M, share buybacks $0
PMCB balance sheet
- Jul 31, 2026: cash $17.7M, total assets $36.7M, total liabilities $6.90M, shareholders' equity $27.5M
- Apr 30, 2026: cash $18.6M, total assets $46.8M, total liabilities $11.8M, shareholders' equity $33.3M
- Jan 31, 2026: cash $20.2M, total assets $55.9M, total liabilities $16.5M, shareholders' equity $38.1M
- Oct 31, 2025: cash $15.4M, total assets $56.0M, total liabilities $19.4M, shareholders' equity $35.2M
- Jul 31, 2025: cash $13.2M, total assets $45.1M, total liabilities $1.52M, shareholders' equity $43.6M
- Apr 30, 2025: cash $15.2M, total assets $55.2M, total liabilities $3.28M, shareholders' equity $51.9M
- Jan 31, 2025: cash $16.4M, total assets $43.8M, total liabilities $3.58M, shareholders' equity $40.3M
- Oct 31, 2024: cash $20.8M, total assets $55.1M, total liabilities $11.6M, shareholders' equity $43.5M
What is PMCB's revenue?
PHARMACYTE BIOTECH INC reported $0 of revenue over its last four quarters, through July 31, 2026.
Is PMCB profitable?
No. PHARMACYTE BIOTECH INC lost $16.1M over the last four quarters.
What is PMCB's EPS?
Diluted earnings per share over the last four quarters were −$2.08; −$0.54 in the latest quarter.